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Background. Given the identity between Neisseria meningitidis serogroup B (MenB) capsular polysaccharide
(polysialic acid; PSA) and PSA found on neural cell adhesion molecules, it has been proposed that infection with
MenB or vaccination with PSA may be associated with subsequent autoimmune or neurological disease.
Methods. We conducted 2 studies. The first was a retrospective nationwide study of invasive meningococcal
disease (IMD) in Iceland (with 541 subjects) during the period 1975–2004, and we cross referenced this cohort with
databases with respect to subsequent diagnosis of autoimmune disorders. A follow-up study involving 120 survivors of
IMD was performed. The study included 70 patients with a history of MenB and 50 patients with N. meningitidis
serogroup C (MenC) infection, who served as control subjects. Participants answered standardized questionnaires
(Beck’s Depression Inventory [BDI] II, Depression Anxiety Stress Scales [DASS], and Patient Health Questionnaire
[PHQ]), and serum levels of immunoglobulin (Ig) G against MenB andMenC capsular polysaccharides were measured.
Results. The nationwide cohort had 9166 patient-years of follow up. No evidence of increased autoimmunity
was found to be associated with MenB, compared with MenC. In the follow-up study, patients were evaluated 16.6
years after the infection, representing 2022 patient-years of observation. Comparable rates of most complications
were recorded, but MenC infections were associated with arthritis (P 5 .008) and migraine headaches (P 5 .01)
more frequently than were MenB infections. No difference was observed with respect to scores on BDI-II, DASS, or
PHQ. IgG anti-MenB and anti-MenC capsular polysaccharide levels were not related to patient complaints.
Conclusions. This study does not support the hypothesis that MenB infection may predispose to
autoimmunity. MenC infections are associated with a higher prevalence of arthritis and migraine headaches. No
evidence of antibody-associated pathology was detected at long-term follow-up.
Invasive meningococcal disease (IMD) represents a
worldwide health problem [1]. The recent incidence of
meningococcal disease is 0.35–1.01 cases per 100 000 in-
habitants in most western countries [2]. In Iceland,
however, the incidence has been 2–3 times higher [3].
In the meningitis belt of sub-Saharan Africa, the incidence
of IMD can approach a staggering 1000 cases per 100 000
inhabitants during epidemics; most of these cases are
caused by group A meningococci [2]. The prognosis of
and case fatality rate among patients affected by IMDhave
not changed significantly over the past 3 decades, and the
infection carries a rate of postinfectious complications of
4.3%–12% [4, 5]. These long-term complications can be
neurological, psychological, or physical in nature and do
not seem to be associated with each other [6]. Neisseria
meningitidis serogroup B (MenB) is the serogroup that is
most commonly found in Icelandic patients, followed by
N. meningitidis serogroup C (MenC) [3]. Since 2002, all
Icelandic children are vaccinated against MenC, which
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has resulted in a significant decrease in the number of cases, but
a universal vaccine against MenB is unavailable [7]. MenB
capsular polysaccharide is composed of a linear homopoly-
mer of a(2/8) N-acetyl-neuraminic acid (polysialic acid; PSA).
PSA is a potential vaccine candidate, but it is poorly immuno-
genic, which is a property attributed to immunologic tolerance
induced by polysialylated glycoproteins that include neural cell
adhesion molecules (PSA-NCAM), which can be found in several
molecular forms. The embryonic form, especially expressed in
neural tissue during development, possesses an unusually large
amount of PSA [8]. Antigenic identity between the carbohydrate
component of this form andMenB PSA has been reported [9, 10].
Antibodies have been detected in patients with MenB meningitis
that bind to embryonic NCAM in mouse embryonic brain cul-
tures [11]. Because of a theoretical risk of autoimmune reactivity
against neural tissue, most vaccine researchers have therefore fo-
cused on antigens other than PSA for MenB [12]. Conversely,
MenC are not known to possess any surface antigens that share
a similarity with surface molecules in human tissues. Therefore,
one way to test the hypothesis of increased autoimmune or
neurological morbidity following PSA exposure is to study in-
dividuals who have been infected with MenB and to use patients
with MenC infection as control subjects. MenC has a capsular
polysaccharide that differs from that ofMenB only by its anomeric
linkage; MenB is a(2/8) andMenC is a(2/9) linked. However,
studies on late complications from IMD are challenging, because
the number of patients required for such studies is difficult to
estimate and a cause and effect relationship is hard to establish.
A population-based study of patients with a history of IMD in
Denmark found no evidence of increased autoimmunity in pa-
tients [13] or adverse birth outcomes in offspring of mothers
following MenB infection [14]. We addressed this problem in
3 ways. First, the incidence of autoimmune disorders was studied
in a population-based cohort with IMD in Iceland with long-term
follow-up. Second, a subset of patients who survived the infection
was recruited for clinical examination and to answer questionnaires
regarding physical and mental well-being. Third, immunoglobulin
(Ig) G anti MenB andMenC capsular polysaccharides were assayed
in this patient subset. Iceland is ideally suited for studies of this
nature, because meningococcal infections are relatively common in
the country; a nationwide registry of all invasive cases has been kept
since 1975, and clinical records are available for review and cross-
referencing with hospital diagnoses.
MATERIALS AND METHODS
Setting and Description of the Invasive Meningococcal Disease
Registry
Iceland is a 103.000 km2 island in the North Atlantic where
Invasive meningococcal disease (IMD) is a notifiable disease,
and a nationwide registry of cases has been kept since 1975. The
country had 216 695 inhabitants in 1975 and 293 577 at the end
of 2004 [15]. During this time, there were 14 hospitals in the
country that provided inpatient services, and all blood cultures
were processed at 2 sites. Cases were classified as IMD if they
fulfilled 1 of the following 2 criteria: a positive culture of N.
meningitidis in blood, cerebrospinal fluid (CSF), or synovial
fluid specimens; or clinical signs of meningococcal infection and
either a positive culture from a throat specimen or a positive
Gram stain result, latex agglutination test result, or PCR result
(since 2002) for meningococci from a normally sterile site.
Retrospective Population-Based Study
Medical records of all patients with IMD in the country during
1975–2004 were reviewed. Information on clinical character-
istics of the patients and their hospital course was registered, in
addition to the serogroup of the meningococcal isolate. To
evaluate the severity of illness, the Glasgow Meningococcal
Septicemia Prognostic Score (GMSPS) and Acute Physiology
and Chronic Health Evaluation II (APACHE II) scoring systems
were used for children and adults, respectively [16, 17]. Missing
values were assumed to be within normal limits. Postinfectious
complications were defined as short-term or long-term com-
plications on the basis of time of onset and duration. Short-term
complications began while the patients were hospitalized and
subsided within 2 weeks of onset. Long-term complications
began while the patient was still hospitalized and had not sub-
sided within 2 weeks or began after discharge from the hospital.
The medical records were searched for subsequent diagnoses of
rheumatic and/or immunological diseases, both manually and
by computerized cross-referencing the patient identifiers with
a broad range of International Classification of Diseases, Ninth
Revision and Tenth Revision codes from hospital registries using
codes similar to those used by Howitz et al [13]. The study was
approved by the National Bioethics Committee of Iceland.
Selection of Subjects for Follow-up Study
From the patient registry described above, 20 patients who
survived the infection but were alive at the time of the study
(January 2007–April 2008) and were considered to have long-
term sequelae were invited to participate in a follow-up study. In
addition, a random sample of 150 survivors of documented
IMD caused by either MenB or MenC infection were initially
informed about the study by mail. They were subsequently
contacted by telephone and invited to participate. This study
was approved by the National Bioethics Committee and Data
Protection Agency of Iceland.
Patient Evaluation During Follow-up
After provision of written informed consent, the participants
were interviewed, and a medical history was obtained. If a child
was included in the study, informed consent was obtained from
the parents or legal guardians. Participants were unaware of the
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serogroup of the infecting isolate. They were asked specifically
about symptoms or conditions that could be attributed to se-
quelae from IMD, neurological, psychological, or autoimmune
process (for example, seizures, cognitive dysfunction, mental
problems, muscle weakness, paralysis, numbness, hearing im-
pairment, rheumatologic diseases, skin diseases, migraine, and
arthritis). They also answered 3 questionnaires regarding their
mental and physical symptoms, Patient Health Questionnaire
(PHQ), measuring somatoform disorder, major depressive
syndrome, other depressive syndrome, panic syndrome, other
anxiety syndrome, bulimia nervosa, binge eating disorder, and
alcohol abuse; Beck’s Depression Inventory II (BDI-II), mea-
suring symptoms of depression; and Depression Anxiety Stress
Scales (DASS), measuring symptoms of depression, anxiety, and
stress, all of which have been validated in Iceland [18–20]. Fi-
nally, a physical examination was performed, and blood samples
were collected.
Measurement of Antibodies to MenB and MenC
Enzyme-linked immunosorbent assay for MenB and MenC
antibodies was performed as previously described [21–23].
Statistical Analysis
Retrospective Study
TheMann–WhitneyU test was used to compare the GMSPS and
APACHE II scores of individuals who survived with the scores
of patients with fatal infection. Fisher’s exact test was used to
compare the mean severity score of patients who received a di-
agnosis with serogroup B infection with that of patients who
received a diagnosis of serogroup C infection. Statistical com-
parison was performed using SPSS software, version 11.0 (SPSS).
Follow-up Study
Data are reported as mean values 6 standard deviations (SDs).
Unpaired t test with Welch correction, paired t test, analysis
of variance, and Fisher’s exact tests were used for comparisons as
appropriate. The Mann–Whitney U test was used to compare
IgG titers in the 2 patient groups. All P values were 2-tailed.
RESULTS
Retrospective Cohort
Overall, 562 patients received a diagnosis of IMD during the
period 1975–2004 in Iceland. Of these, the medical records of
541 (96%) were available for review. The 30-day case fatality rate
in this group was 7.9% (43 of 541 patients died). Of the me-
ningococcal isolates, MenB was most commonly identified (in
261 patients; 48.2%), followed by MenC (154; 28.5%), sero-
group A (20; 3.7%), and serogroups Y and W-135 (3 each;
0.6%). Information about the serogroup was not available for
100 cases (18.5%). As reported previously, the most common
sequence types (ST) in Iceland during the period 1977–2004
were ST 32, ST 11, ST 10, and ST 3492 (part of the ST41/44
complex) [3].
An overview of complications in the retrospective cohort is
shown in Table 1. As shown, these were most commonly ar-
thritis, acute renal failure, and hearing loss. Arthritis was di-
agnosed more often in patients with MenC than in patients with
MenB infections (P , .001), but the prevalence of other com-
plications was not statistically different between the 2 groups.
Other less common long-term health problems were epilepsy
(3 patients; 0.6%), migraine headaches (3), and pericarditis (3).
The following diagnoses were made in 1 patient each: adrenal
insufficiency, psoriasis, strabismus, Henoch–Scho¨nlein purpura,
impaired coordination, rheumatoid arthritis (RA), and systemic
lupus erythematosus (SLE). The patient with SLE had IMD
caused by MenC and subsequently received a diagnosis of C2
complement deficiency that was believed to be preexisting and
that predisposed him to both IMD and SLE. The patient registry
was cross-referenced with hospital discharge diagnoses to detect
potential associations with autoimmune diseases following the
















B 7 6a 5 4 8 4 10 261
C 3 21a 7 6 4 2 5 154
Y 3
W-135 3
Unknown 3 4 3 3 2 2 1 100
Total 13 31 15 13 14 8 16 541
Acute and long-term complications by meningococcal serogroups in a cohort of 541 patients in Iceland. The far right column shows the number of infections caused
by individual serogroups in the cohort.
a P , .001 for B versus C.
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diagnosis of IMD during 9166 person-years of observation. Only 3
patients were found; the results are shown in Table 2. The patient
with RA had already been identified, but 2 additional patients
received a diagnosis of diabetes mellitus 18–21 years after IMD.
Follow-up Study of Survivors
Of the 170 patients that were offered the opportunity to par-
ticipate in the study, 120 (70.6%) accepted. Of the remaining
patients, 8 (4.7%) declined to participate, 14 (8.2%) could not be
contacted, 22 (12.9%) could not participate for geographical
reasons, and 6 (3.5%) agreed to participate but repeatedly
missed appointments. Characteristics of participants are shown
in Table 3. The total follow-up period was 2022 years for the
entire cohort. Patients infected with MenB had longer follow-up
than did those infected with MenC (P , .001). As shown, pa-
tients infected withMenB were, on average, infected at a younger
age, and children with MenB had significantly less severe disease,
compared with children withMenC (P5 .02). Although average
APACHE II scores for adults were higher among patients with
MenC, the difference did not reach statistical significance.
Evaluation During Follow-up
The patients were questioned about their health following the
meningococcal infection (Table 4). Patients with MenC disease
reported migraine headaches and previous or current arthritis
(P , .01 and P 5 .008, respectively) more frequently than did
patients withMenB disease. One patient withMenC disease, also
identified in the retrospective study, had received a diagnosis
of SLE. Other autoimmune disorders were not reported. The
results of a physical examination, including vital signs and
neurological examination findings, are shown in Table 5. The
results were similar, with no significant statistical difference in
any of the categories between the 2 groups.
Questionnaires on Physical and Mental Health
Results from the 2 questionnaires measuring symptoms of de-
pression, anxiety, and stress (BDI-II; DASS) are shown in Table 6.
No difference was observed between patients infected with
MenB or MenC with reference to self-reported depressive
symptoms, anxiety, and stress-related symptoms. Table 6 also
lists mean scores from the general public for reference. No dif-
ference was observed between the patient groups and the general
public with respect to depressive scores and stress-related
symptoms. However, both MenB [t(55)5 22.93; P , .05] and
MenC patients [t(42) 5 22.24; P , .05] had lower scores than
did the reference group with respect to anxiety (table 6). Ac-
cording to the PHQ, 27.9% of participants with MenB diseases
and 26.1% of participants with MenC disease had screening
results that were positive for any of the 8 mental symptoms that
the questionnaire measures (P5 .83). In a sample of outpatients
in primary care in Iceland [24], 26.3% had screening results that
were positive for any of the 8 mental symptoms using the same
Table 2. Autoimmunity in Retrospective Cohort
Age, years, at time
of infection Sex Serogroup
Clinical
manifestation Diagnosis, ICD-10 code
Years after
infection
14.7 M C Meningitis Rheumatoid arthritis, unspecified, M06.9 0
12.7 M Unknown Meningitis Insulin-dependent diabetes mellitus, E10.0 18
3.3 M B Sepsis Non–insulin-dependent diabetes mellitus, E11.8 21
The total observation time was 9166 person-years. Three patients subsequently received a diagnosis of autoimmune disease. ICD-10, International Classification of
Diseases, Tenth Revision.
Table 3. Follow-up Study of Survivors
Variable MenB (n 5 70) MenC (n 5 50) Total (n 5 120) P
Age at time of infection, mean years (6SD) 9.3 6 11.7 17.6 6 16.8 12.7 6 14.6 ,.002a
Current age, mean years (6SD) 29.1 6 13.3 30.0 6 16.3 29.5 6 14.6 .72
Cumulated years of observation 1404.5 617.9 2022.4 ,.001a
Male sex, proportion (%) 32/70 (46) 22/50 (44) 54/120 (45)
APACHE IIb (6SD) 7.6 6 5.2 9.2 6 6.9 8.5 6 6.2 .37
GMSPSc mean (6SD) 1.9 6 2.2 2.7 6 2.3 2.2 6 2.3 .02a
At the time of evaluation, the cohort had accrued a total of 2022 years of follow-up. One patient had 2 separate infection episodes due to MenB.
Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; GMSPS, Glasgow Meningococcal Septicemia Prognostic Score; SD, standard
deviation.
a Two-tailed independent t test.
b n 5 20 for MenB (only the first episode was counted in a single patient with recurrent infection), n 5 22 for MenC.
c n 5 50 for MenB, n 5 28 for MenC.
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criteria. The difference between the 2 samples was not significant
(P 5 .80 and P 5 .97 for MenB and MenC, respectively). In
patients with MenB, 21.3% fulfilled the PHQ criteria for alcohol
abuse, and in patients with MenC, 17.4% fulfilled these criteria.
This difference was not significant (P 5 .61).
Antibody Measurements
IgG levels against MenB capsular polysaccharide were similar
in the 2 groups (MenB [median IgG, 6.0 EU/mL] and MenC
[6.6 EU/mL]; P 5 .345). In contrast, patients with a history of
MenC disease had significantly higher IgG to MenC capsular
polysaccharide (median IgG, 5.9 EU/mL) than did patients with
MenB (median, 2.3 EU/mL; P5 .009). No difference was noted
between the MenB IgG levels in persons with arthritis and in
those without arthritis (P 5 .592). Similarly, no significant
differences were detected between MenB IgG levels in subjects
with migraine headaches and in those without migraine head-
aches (P 5 .207), and no significant differences were detected
between IgG to MenC capsular polysaccharide levels in subjects
with arthritis and in those without arthritis (P 5 .414) or in
those with migraine and in those without migraine (P 5 .687).
Table 4. Follow-up Study of Survivors Self-Reported Health






(n 5 50) Total P
Seizures/seizure disorder 4 0 4 .14
Cognitive problems 17 16 33 .41
Mental problems 14 9 23 .82
Depression 4 3 7 ..99
Anxiety 5 2 7 .70
Depression/anxiety 2 0 2 .51
NOS 5 3 8 ..99
Muscle weakness 3 4 7 .45
Paralysis 0 1 1 .42
Numbness 3 3 6 ..99
Hearing impairment 9 7 16 .92
Autoimmune disease 0 1 1 .42
Skin disease 15 7 22 .42
Eczema 3 2 5 ..99
Psoriasis 3 0 3 .26
NOS 9 5 14 .78
Migraine 7 15 22 .01
Arthritis 2 9 11 .008
Abbreviation: NOS, other diagnoses or not otherwise specified.
Table 5. Follow-up Study of Survivors Results of Physical Examination
Health problem Serogroup B (n 5 70) Serogroup C (n 5 50) Total
General examination
Skin scarring 1 1 2
Vital signs
Systolic blood pressure, mean mm Hg (6SD) 124 6 17 122 6 15
Diastolic blood pressure, mean mm Hg (6SD) 79 6 10 77 6 10
Heart rate, mean beats/min (6SD) 70 6 12 74 6 11
Arterial pressure, mean mm Hg (6SD) 94 6 11 92 6 11
Neurological abnormalities
Cranial nerves
Smell and taste 1 1 2
Esotropia 1 0 1
Hearing impairment 6a 9e 15
Facial sensorium 5b 0 5
Touch/pain 3c 4f 7
Vibrationd 2 3 5
Strength 1 2 3
Reflexes 5 5 10
Proprioception 1 2 3
No statistical difference was observed between the 2 groups in any of the categories.
a Of the 6 patients with MenB and hearing impairment, 1 developed hearing impairment following acute otitis and 1 developed hearing impairment following an
explosion.
b At least 2 due to causes other than invasive meningococcal disease.
c One secondary to surgery.
d Defined as ,6/8.
e Two instances believed secondary to acute otitis.
f Two cases secondary to diabetes and herniated disc.
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DISCUSSION
This study addresses the prevalence of both acute complications
and long-term health among patients with IMD. Retrospective
analysis was performed of all cases diagnosed in the country
during a 30-year period, and a cohort of survivors with a history
of MenB or MenC disease was recruited to study the long-term
health of the patients. The sample was population-based, par-
ticipation was high, and the cohort included representative
survivors of IMD. The severity of invasive disease was greater in
patients with MenC, and arthritis was more commonly identi-
fied in patients with MenC than in patients with MenB. Disease
severity, case fatality rate, and the rate of sequelae have been
shown to be significantly higher in children with MenC than in
children withMenB diseases [25–27]. In the retrospective part of
this study, skin scarring was reported in 2.4%, which is sub-
stantially lower than figures from a large study in Quebec,
Canada (7.7%) [27]. In the Canadian study, the risk of skin
scarring and amputations was associated with serogroup C,
which was associated with two-thirds of the cases [27]. In
contrast, serogroup C caused 37% of all IMD cases with a known
serogroup in our study. On the other hand, we identified
a higher prevalence of hearing loss and renal failure (2.6% and
2.8%, respectively, compared with 1.9% and 0.7% in Quebec).
Although it is conceivable that complications of IMD may be
dependent on specific interactions between the host and the
pathogen, including the serogroup of the isolate, they could also
be explained by differences in documentation in the 2 studies.
Meningococcal arthritis can result from direct infection of the
joint space, which is relatively rare, or from type III immune
complex–mediated inflammation, which is believed to be more
common [28]. These complications are noted in 5% of children
and 11%–12% of adults with IMD [29, 30]. Based on our data,
patients with MenC were significantly more likely than were
MenB patients to develop arthritis. It has been postulated that
pericarditis, which may have a similar pathogenesis, may be
more prevalent in MenC infections [31]. In our follow-up study,
no difference in antibody titers was noted between patients who
reported arthritis and those who did not.
Interestingly, patients with MenC were more likely than pa-
tients withMenB to report migraine headaches during follow-up.
This has not been previously reported and warrants further study.
Similar to the results of Howitz et al [13], we detected no increase
in autoimmune disorders in the MenB cohort, compared with
that of the MenC cohort, but the number of cases was low.
Antibodies of patients with a history of MenBmeningitis have
been reported to react in vitro against the embryonic form, but
not the adult form, of NCAM in cell cultures from mice [11]. In
addition, patients as young as 3 years of age recovering from
MenB disease demonstrate both serum IgM and IgG antibody
response against the capsular polysaccharide of MenB [32].
NCAM may be important for regeneration of neural tissue,
including promotion of Schwann cell migration [33]. Therefore,
it was of interest to compare patients with MenB and patients
with MenC with respect to neurological symptoms and symp-
toms of depression, anxiety, and stress. Borg et al [26] recently
demonstrated that children who survived IMD had greater de-
pressive symptoms and greater fatigue at 18–36 months after the
infection, compared with matched control subjects, but no dif-
ference was noted between patients infected withMenB and those
infected with MenC. Our study addresses a similar issue, with
2 important exceptions: the timing of follow-up was, on average,
more than a decade later, and participants were not exclusively
children at the time of the infection. Nevertheless, the prevalence
of mental health complaints was similar overall in the 2 groups.
Therefore, although poorer mental functioning has been dem-
onstrated in children at 18–36months after IMD [26], our results
do not suggest that psychiatric morbidity is permanently in-
creased in the survivors at long-term follow-up. The results
therefore provide support for the notion that psychological
functioning continues to improve slowly during the first decade
after the infection [34]. At the time of follow-up, the IgG titers
against MenB were not significantly different between the groups,
whereas prior MenC infection was associated with higher MenC
Table 6. Follow-up Study of Survivors Results of Mental Health Questionnaires Scores
Serogroup T value
Scale B (n 5 56) mean (SD) C (n 5 43) mean (SD) F value Reference mean B C
DASS-D 3.2 (6.1) 4.1 (7.1) 0.43 4.58 21.68 20.45
DASS-A 2.5 (4.4) 3.0 (3.7) 0.60 4.26 22.93a 22.24a
DASS-S 6.5 (6.4) 6.4 (7.8) 0.90 7.57 21.24 20.99
BDI-II 7.6 (8.1) 6.6 (8.6) 0.37 8.80 21.05 21.72
DASS-D, DASS-A, DASS-S, and BDI-II are presented according to the serogroups of the invasive meningococcal isolates. No difference appeared between MenB
and MenC patients with respect to any of the scores. Scores for a reference group of students are also shown, showing a significantly lower anxiety scores for the
patients.
Abbreviations: BDI-II, Beck’s depression inventory II, DASS-A, Depression Anxiety Stress Scale for anxiety; DASS-D, Depression Anxiety Stress Scale for
depressive symptoms; DASS-S, Depression Anxiety Stress Scale for stress; SD, standard deviation.
a P , .05.
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titers. Almost all adults have ‘‘natural’’ MenB (and C) antibodies
that are most likely induced by cross-reactive organisms such as
Escherichia coli K1 [12]. Disease-induced antibody levels have
likely waned with time, leaving similar levels in both groups.
In Iceland, the incidence of MenB disease has historically been
higher than the incidence of MenC disease [3]. Therefore, in this
study, the number of patients with MenB was greater, and their
follow-up was longer, which increases the chances of finding an
association of this serogroup with long-term sequelae. It should be
cautioned that the incidence of most autoimmune diseases is low,
and the study may lack statistical power to detect a small increase
in risk (type II error). Nevertheless, the results are consistent with
those of 2 previous studies from Denmark that showed no evi-
dence of increased autoimmunity or adverse birth outcome after
MenB disease [13, 14]. Another potential weakness of the study is
the use of patients with MenC, rather than age-matched healthy
controls, as a control group. We believe, however, given the rel-
atively high risk of sequelae following IMD [4], that patients with
MenC were a more relevant comparison group for invasive MenB
infection than was the general population. Another potential
weakness is the assumption that natural infection with MenB
produces serum antibody responses that are identical to vacci-
nation with a PSA-based vaccine. Experiences with vaccines,
however, including polysaccharide conjugates with other capsu-
lated pathogens, have not shown qualitative differences in the
serum antibody levels induced by infection or by vaccination.
In summary, results from this long-term nationwide study do
not support a link between MenB infections and autoimmunity,
neurological or mental symptoms. MenC infections were more
severe than were MenB infections, especially in children. During
long-term follow-up, antibody levels are generally low in pa-
tients with a history of IMD, and no association was noted
between IgG titers to MenB or MenC and patient complaints. In
our opinion, additional studies of PSA as a potential vaccine
candidate against MenB should not be ruled out on the basis of
theoretical concerns alone.
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